Latest News: ReSPECT™ Glioblastoma Clinical Trial Data To Be Presented At SNO Meeting
USING INNOVATIONS TO ADDRESS LIFE-THREATENING DISEASES
Watch The Experts
“New treatments for (recurrent glioblastoma) are critical to making an impact for these patients.”
Marc Hedrick, MD
President & Chief Executive Officer of Plus Therapeutics
“Radiation has made the biggest dent in terms of how long people live.”
Andrew Brenner, MD PhD
Principal Investigator of U.S. NIH/NCI-Supported Phase 1 Clinical Trial
Mays Cancer Center / UT Health San Antonio MD Anderson Cancer Center
Development Is In Our DNA
There are many reasons why we believe we possess the capacity and experience to develop and manufacture large-scale, sophisticated nanotechnology-encapsulated cytotoxic drugs that successfully meet patient needs around the globe:
A fully GMP-compliant, validated, state-of-the-art, U.S. development and manufacturing facility supported by an ICH-compliant Quality Management System.
A 10,000 square foot space with ISO Class 7 and 8 cleanrooms, including a negative pressure room for managing hazardous drugs.
A dedicated analytical chemistry lab with multiple High Performance Liquid Chromatography (HPLC) systems with multiple detector capability, an environmental monitoring lab, and a fully qualified Water For Injection (WFI) system onsite.
Decades of drug delivery development experience with combination products and liposomal encapsulation, resulting in the completion of multiple successful clinical trials in the U.S. and internationally.
Selective Tumor Targeting
While nanotechnology-based drug delivery systems have been used clinically for some time, not all of them are equally effective. We are taking a unique design approach with widely-used chemotherapy drugs, using our patented liposomal formulation to elevate drug delivery and performance.
